Article Text
PDF
Abstract
Introduction Major clinical practice guidelines recommend assessing risk of cardiovascular disease (CVD) using absolute/global/total CVD risk scores. However, the effectiveness of using them in clinical practice, despite publication of numerous randomised controlled trials (RCTs), is still poorly understood. To summarise and analyse current knowledge in this field, we will carry out an overview of existing systematic reviews (SRs). The objective of this overview will be to assess the effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of CVD compared with standard care.
Methods and analysis We will include SRs and meta-analyses which take into account RCTs and quasi-RCTs investigating the effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of CVD. SRs will be retrieved from 4 bibliographical databases and reference lists of identified reviews. Additionally, the PROSPERO database will be searched for unpublished, ongoing or recently completed SRs. 2 reviewers will assess the SRs independently for eligibility and bias. The data will be extracted to a special form. Any disagreement will be resolved by discussion. In case of lack of consensus, a third author will arbitrate. The overview of SRs will be reported according to the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) statement.
Ethics and dissemination Ethics approval is not required for overview of SRs. We will summarise evidence concerning whether use of the absolute/global/total CVD risk scoring tools in primary prevention of CVD is effective and supported with scientific data or not. If we face unsatisfactory confirmation, we will highlight a need for further research and advice on how to plan such a study. We will submit the results of our study for peer-review publication in a journal indexed in the international bibliographic database of biomedical information.
- Cardiovascular Diseases
- Primary Prevention
- Risk Assessment
- Cardiovascular System
- Risk Factors
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Statistics from Altmetric.com
Footnotes
Contributors KS and TT conceived the study design. KS, TT, JK, JJ and AW contributed to developing the methods. KS, JK and TT developed the search strategy. JJ and AW provided methodological expertise. KS and TT drafted the protocol manuscript. KS, TT, JK, JJ and AW read, provided feedback on and approved the final manuscript.
Funding This work was supported by the Jagiellonian University Medical College, internal grant number K/ZDS/005672. Publication was supported by the Faculty of Medicine of Jagiellonian University Medical College (Leading National Research Centre 2012–2017).
Competing interests TT reports personal fees from AbbVie Polska Sp. z o.o., personal fees from Pfizer Polska Sp. z o.o., non-financial support from VALEANT POLSKA sp. z o.o. sp. j., outside the submitted work. JJ reports personal fees from VALEANT personal fees from MYLAN, non-financial support from CHDE, non-financial support from AMGEN, outside the submitted work. AW reports personal fees from MSD Polska sp. z o.o., personal fees from Merck sp. z o.o., personal fees from Sanofi-Aventis sp. z o.o., personal fees from Polpharma SA, outside the submitted work.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement The authors will submit the results of the study for peer-review publication in a journal indexed in the international bibliographic database of biomedical information.